- Zoetis (NYSE:ZTS) initiated wit Buy rating with a $60 (18% upside) price target by Bank of America.
- Akebia Therapeutics (NASDAQ:AKBA) initiated with Buy rating and $18 (106% upside) price target by Brean Capital.
- DexCom (NASDAQ:DXCM) initiated with Neutral rating and $97 (10% upside) price target by B. Riley.
- vtv Therapeutics (NASDAQ:VTVT) initiated with Buy rating and $13 (82% upside) price target by H.C. Wainwright.
- ARIAD Pharmaceuticals (NASDAQ:ARIA) initiated with Outperform rating by Leerink Swann.
- Aldeyra Therapeutics (NASDAQ:ALDX) initiated with Buy rating and $18 (139% upside) price target by H.C. Wainwright.
- Lantheus Holdings (NASDAQ:LNTH) initiated with Neutral rating and $8 (1% upside) price target by Credit Suisse.
- BioTime (NYSEMKT:BTX) initiated with Buy rating and $6 (63% upside) price target by Ladenburg.
- Sanofi (NASDAQ:SNY) initiated with Neutral rating by Piper Jaffray.